Evidence map›Paper›PMID 38874019›Full record

ArticleOncology reports2024

2‑D08 mediates notable anticancer effects through multiple cellular pathways in uterine leiomyosarcoma cells.

Hosouk Joung, Hyunju Liu

Abstract read
In one paragraph

Article in Oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hosouk JoungResearch Institute of Medical Sciences, Chonnam National University Medical School, Hwasun, Jeonnam 58128, Republic of Korea.
Hyunju LiuDepartment of Obstetrics and Gynecology, Chosun University College of Medicine, Gwangju 61452, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

2',3',4'‑trihydroxyflavone (2‑D08), a SUMO E2 inhibitor, has several biological functions, including anticancer activity, but its effects on uterine leiomyosarcoma (Ut‑LMS) are unknown. The anticancer activity of 2‑D08 was explored in an

Indexed as

ApoptosisCell ProliferationLeiomyosarcomaUterine NeoplasmsAntineoplastic AgentsAutophagyCell CycleCell Line, TumorCell SurvivalFemaleFlavonesGene Expression Regulation, NeoplasticHumansReactive Oxygen SpeciesSignal TransductionAntineoplastic AgentsFlavonesReactive Oxygen Species2‑D08apoptosisleiomyosarcomaproliferationSK‑LMS‑1SK‑UT‑1Buterine

Identifiers

PMID38874019
PMCPMC11200159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.